Congenital hyperinsulinism/hyperammonemia (HI/HA) syndrome gives rise to unregulated protein-induced insulin secretion from pancreatic beta-cells, fasting hypoglycemia and elevated plasma ammonia levels. Mutations associated with HI/HA were identified in the Glud1 gene, encoding for glutamate dehydrogenase (GDH). We aimed at identifying the molecular causes of dysregulation in insulin secretion and ammonia production conferred by the most frequent HI/HA mutation Ser445Leu. Following transduction with adenoviruses carrying the human GDH-wild type or GDH-S445L-mutant gene, immunoblotting showed efficient expression of the transgenes in all the investigated cell types. Enzymatic activity tested in INS-1E beta-cells revealed that the mutant was much more sensitive to the allosteric activator ADP, rendering it highly responsive to substrates. INS-1E cells expressing either the wild type or mutant GDH responded similarly to glucose stimulation regarding mitochondrial activation and insulin secretion. However, at basal glucose glutamine stimulation increased mitochondrial activity and insulin release only in the mutant cells. In mouse and human islets, expression of mutant GDH resulted in robust elevation of insulin secretion upon glutamine stimulation, not observed in control islets. Hepatocytes expressing either the wild type or mutant GDH produced similar levels of ammonia when exposed to glutamine, although alanine response was strongly elevated with the mutant form. In conclusion, the GDH-S445L mutation confers hyperactivity to this enzyme due to higher sensitivity to ADP allosteric activation. This renders beta-cells responsive to amino acid stimulation, explaining protein-induced hypoglycemia secondary to non-physiological insulin release. Hepatocytes carrying mutant GDH produced more ammonia upon alanine exposure, which underscores hyperammonemia developed by the patients.
Introduction
Glutamate dehydrogenase (GDH) is an enzyme forming a homohexamer in the mitochondrial matrix and is encoded by the nuclear gene GLUD1, which is organized into 13 exons (1, 2) . GDH catalyzes the reversible reaction a-ketoglutarate þ NH 3 þ NADH $ glutamate þ NAD þ and is allosterically regulated by leucine, pyridine, adenine and guanine nucleotides (3, 4) . Each subunit of GDH exhibits specific binding domains: the catalytic domain, the adenine and guanine nucleotide regulatory domains, the reduced coenzyme regulatory domain, and the ADP-ribosylation domain (2, 5) . In most vertebrates GDH is under the control of allosteric modulators, i.e. inhibited by GTP and activated by ADP (2) . GDH is also regulated by reversible cystein-specific ADP-ribosylation. In the pancreatic b-cell, mitochondrial ADPribosyltransferase SIRT4 downregulates GDH activity and thereby inhibits insulin secretion (6, 7) . Identification of an unusual congenital hyperinsulinism/ hyperammonaemia (HI/HA) syndrome has been associated with dominant activating mutations in GDH, most of them resulting in reduced GTP-mediated inhibition of the enzyme (8) . Some of the activating mutations of GDH are associated with HI/HA as well as epilepsy (9) . HI/HA patients show unregulated proteininduced insulin secretion, fasting hypoglycaemia, and elevated plasma ammonia levels. GDH-Ser445Leu (GDH S445L ) is the most frequent GDH mutation, giving rise to both HI/HA and epilepsy (10) . However, the GDH S445L mutation remains poorly characterized; primarily at the protein level in terms of molecular and enzymatic impairments and also regarding dysfunction of specific tissues, in particular the pancreatic b-cell and the hepatocytes.
Studied in different organs, the specific functions of GDH have been previously investigated, although the HI/HAassociated GDH mutations further demonstrate its importance and its tissue-specificity in terms of metabolic regulation. In the pancreatic b-cells, GDH has been shown to participate to glucose-stimulated insulin secretion through the formation of glutamate that is required for the amplifying pathway of the secretory response (11) (12) (13) . Indeed, upon glucose stimulation, the activation of the TCA cycle generates a-ketoglutarate and NADH, thereby promoting reducing activity of GDH that produces glutamate, in turn enhancing calcium-induced insulin exocytosis (11) (12) (13) . The reverse GDH oxidative activity feeding the TCA cycle is not favoured in normal b-cells, as demonstrated by the lack of secretory response upon glutamine exposure (14, 15) . In this context, it is noteworthy that patients with HI/HAassociated hyperactive GDH mutants present protein-induced hyperinsulinemia and, as a consequence, hypoglycaemia (16) .
In the hepatocytes, GDH participates in ammonia detoxification, NH 3 being eliminated through the urea cycle. GDH is ubiquitously expressed, although in the liver GDH represents as much as 1% of total proteins (17) and its enzymatic activity is 4.5-fold higher than in other tissues (18) . Ammonia derived from the diet or generated by the skeletal muscles, the kidney and the brain is mostly detoxified in the periportal hepatocytes (19) . During fasting conditions, amino acids are released from the muscles in the blood, mainly in the form of alanine and glutamine, and then taken up by the liver for neoglucogenesis. These pathways produce ammonia both by glutamine deamidation and by glutamate deamination, the latter reaction being catalysed by GDH. In HI/HA patients, activating mutations of GDH are associated with elevated plasma ammonia levels (16) .
GDH mutations found in HI/HA patients are generally sporadic and heterozygous but the hyperactive mutant forms are dominant (10) . The aim of the present study was to uncover the molecular defects of GDH S445L , the mutant GDH most frequently observed in HI/HA patients (10) , and to characterize its effects on the b-cells and the hepatocytes in order to elucidate the associated hyperinsulinism and hyperammonemia, respectively. For this purpose, human wild-type GDH (hGDHwt) or S445L mutant GDH (hGDH S445L ) were expressed by adenoviral transduction in insulin secreting cells (INS-1E b-cells, mouse and human pancreatic islets) and isolated mouse hepatocytes. This allowed identification of ADP as the allosteric modulator responsible for hyperactive hGDH S445L . The mutation rendered the b-cells responsive to glutamine for insulin secretion and the hepatocytes produced more ammonia upon alanine exposure; recapitulating protein-induced hyperinsulinism and hyperammonemia.
Results
Mutant GDH activity and dose-response to substrates and co-substrates
The INS-1E b-cells were transduced with adenoviruses ($ 10 ifu/ cell) expressing the human GDH wild-type (hGDHwt) or mutant enzyme (hGDH S445L ) respectively. The efficiency of ectopic expression of both the hGDHwt and the hGDH S445L over the endogenous GDH (none) was confirmed by immunoblotting (Fig. 1A) , showing similar hGDH levels in transduced cells. INS-1E cell extracts were used for in vitro biochemical characterization of the enzymatic activity of hGDHwt and hGDH S445L through doseresponses to substrates and co-substrates in both the anaplerotic and the cataplerotic directions. Activity of endogenous GDH measured in the non-transduced cells accounted for about 10% of the activity measured in the transduced cells (data not shown). The enzymatic activity was first evaluated in the anaplerotic oxidative reaction using increasing concentrations of the substrate glutamate (Glu) and the co-substrate NAD þ , expressed as rate of product formation per ng of GDH enzyme (mU/ ng per min). As shown in Figure 1B , the activities of both the wild-type and the mutant GDH were below detection (BD) at glutamate concentrations under the mM range or in the absence of co-substrate NAD þ . At 2 mM glutamate, the GDH activity in the presence of 1.4 mM NAD þ was higher for the mutant compared to the wild-type, a trend that was conserved at higher glutamate concentrations up to maximal velocity (Fig. 1B) . At 5 mM glutamate, the responses to increasing concentrations of NAD þ were similar between hGDH S445L and hGDHwt (Fig. 1B) .
GDH enzymatic activity was also tested in the cataplerotic reductive direction using increasing concentrations of a-ketoglutarate (aKG) as the substrate at 1 mM NADH as the cosubstrate (Supplementary Material, Fig. S1A ). Up to 0.6 mM aKG, the enzymatic activity of both hGDHwt and hGDH S445L were similar, while the mutant GDH exhibited much higher activity compared to the wild-type above this substrate threshold, reaching a plateau at about 5 mM aKG. This first set of data shows that, in the absence of allosteric regulators, hGDH S445L is more active than the wild-type form under specific substrate concentrations.
Mutant GDH and its sensitivity to allosteric modulators
Sensitivity of hGDHwt and hGDH S445L to the allosteric modulators ADP (activator) and GTP (inhibitor) was then tested in extracts of transduced INS-1E cells. First, GDH responses to the activator and the inhibitor were measured in the anaplerotic oxidative direction using 5 mM glutamate as substrate and 1.4 mM NAD þ as co-substrate. In the absence of GTP, enzymatic activities of hGDHwt and hGDH S445L were both dose-dependently induced by increasing concentrations of ADP, while the mutant was more sensitive to ADP activator ( Fig. 2A) . Next, GDH sensitivity to the activation by ADP was measured again without GTP but in the cataplerotic reductive direction using 5 mM aKG as substrate and 1 mM NADH as co-substrate. In this direction, the wild-type GDH robustly responded to ADP but only when its concentration reached 1 mM (Fig. 2B ). In contrast, the mutant hGDH S445L positively responded to ADP activation with induced activity higher than the wild-type already at 20 mM ADP.
The GTP dose-response in the presence of 1 mM ADP showed similar inhibition of the anaplerotic oxidative activities of the mutant and the wild-type GDH, with half activity at about 10 mM GTP (Fig. 2C) . However, in the presence of 250 mM ADP (Fig. 2D) , the sensitivity to GTP-mediated inhibition was right-shifted in hGDH S445L versus hGDHwt, the activity of the mutant remaining higher than the wild-type up to 5 mM GTP (Fig. 2D) . The allosteric inhibitor GTP was also tested in the cataplerotic reductive direction. In these conditions, efficient inhibition of hGDHwt activity was achieved even at the lowest GTP concentration, either without or with 1mM ADP (Supplementary Material, Fig. S1B and C) . Regarding mutant GDH, the combination of the allosteric activator ADP with the inhibitor GTP revealed that the elevated activity of hGDH S445L remained sensitive to GTP-mediated inhibition (Supplementary Material, Fig. S1C ).
According to the hypersensitivity of hGDH S445L to the allosteric activation of cataplerosis by ADP (Fig. 2B) , we tested doseresponses of the substrate aKG at different concentrations of ADP in the presence of the inhibitor GTP (5 mM). Without ADP, GTP-mediated inhibition was effective and exhibited similar effects on both wild-type and mutant GDH at all the concentrations of aKG tested (Supplementary Material, Fig. S2A ). In the presence ADP, the hGDHwt enzyme was kept at basal rate by 5 mM GTP at all of the tested concentrations of aKG, while GTP-mediated inhibition of hGDH S445L was relieved by ADP, the mutant GDH exhibiting robust and dose-dependent elevation of its activity in response to increasing concentrations of aKG (Supplementary Material, Fig. S2B and C) .
These results show the high sensitivity of mutant hGDH S445L to the allosteric activator ADP and the preserved, although right-shifted, GTP-mediated inhibition.
Mutated human GDH form (hGDH S445L ) dynamics
The enzymatic characterization points to an altered sensitivity of hGDH S445L to the allosteric activator ADP. GDH is a homohexameric enzyme composed by two trimers of subunits symmetrically disposed on the top of each other. A protrusion "antenna" region is located over each subunit and is involved in the allosteric regulation of the enzyme (20) . When the enzyme is in the open conformation, it can bind the substrates and co-substrates in order to start a new catalytic cycle generating the abortive complex represented by GDH þ a-KG þ NAD þ (in the reductive cataplerotic reaction) or by the GDH þ glutamate þ NADH (in the oxidative anaplerotic reaction) (20) . Figure 3 shows a model based on the available structural data (4,21-23) of GDH showing the point mutation S445L and its localization to the antenna, just above the ADP binding site. The open conformation of GDH is favored by the binding of ADP to the allosteric activator-binding site, which is located below the antenna. On the contrary, GTP binding next to the pivot helix favors the closure of the GDH catalytic cleft and it stabilizes the closed conformation and abortive complexes ( Fig. 3A and B) . The closed conformation relies on the region of the descending helix in the antenna harboring the S445L mutation to give up some of its a-helical conformation and to insert between the neighboring ascending helices of the antenna ( Fig. 3B and C) . We propose that this "wedge" expands the diameter of the antenna and helps the ascending helices to press against the pivot helices, helping to close the active sites. The serine to leucine mutation introduces a bulkier sidechain, which is likely to disfavor the descending helix from inserting in between the ascending helices, thereby making it easier for ADP to induce the open state, release of abortive complexes and higher enzymatic turnover
Mitochondrial function in INS-1E b-cells expressing hGDH S445L
In the pancreatic b-cells, glutamine is not efficiently catabolized to the end-product CO 2 , unlike glucose, although it is deamidated to glutamate without promoting further TCA cycle activation and ATP generation (24) . Accordingly, glutamine on its own is not a secretagogue. However, the complete oxidation of glutamine can be induced by BCH-mediated allosteric activation of GDH, an effect correlating with the stimulation of insulin secretion (11, 15) . Therefore, under normal conditions, both a low blood glucose state, corresponding to fasting glycemia, and elevated circulating glutamine, produced by the muscles under starvation, are associated with non-stimulated insulin secretion. However, in HI/HA patients fasting can cause a further decrease of plasma glucose and such patients are also subjected to protein-induced hypoglycemia (10) . In this context, we investigated the effects of the HI/HA hGDH S445L mutation on mitochondrial metabolism and insulin secretion in the INS-1E bcells stimulated with either glucose or glutamine. how, in the presence of GTP, the region around S445 (cyan borders) inserts itself like a wedge (arrow heads) between the ascending helices (circles) of the antenna. This stabilizes the widening of the antenna diameter, which puts pressure onto the pivot helices and at the same time fixes the N-termini of the pivot helices, thereby defining the hinge around which the helices rotate.
induced by the protonophore FCCP drives maximal NADH reoxidation to NAD þ by Complex I of the electron transport chain, independently of ATP production. Under these uncoupled conditions, two mitochondrial dehydrogenases, GDH and Complex I, compete for the oxidation of NADH produced by the TCA cycle. Interestingly, when glucose was the only substrate O 2 consumption was higher in the wild-type cells compared to the mutant cells (Fig. 4B) . Upon glucose stimulation, the cataplerotic direction of GDH is favored, thanks to the elevation of both aKG and NADH. The results suggest that in this experimental condition the hyperactive hGDH S445L consumed NADH faster than the hGDHwt, thereby lowering NADH availability for complex I and respiration in the mutant. When cells with uncoupled mitochondria were stimulated with glutamine, O 2 consumption rate was similar between the mutant and the wild-type cells. This indicates that, when mitochondria were uncoupled, the ratelimiting step for respiration upon glutamine exposure was the Complex I, supplying the co-substrate NAD þ used for the anaplerotic direction of GDH (Fig. 4B) . When normally coupled, the mitochondria produce ATP, a production that can be calculated from the OCR. Glucose stimulation induced similar ATP rises in INS-1E cells expressing the hGDHwt versus the hGDH S445L (Fig. 4C) . Glutamine stimulation failed to increase ATP in the wild-type cells, while the mutant cells responded by generating ATP. This profile was confirmed by measuring the absolute values of cellular ATP by bioluminescence assay in extracts of INS-1E cells. Indeed, glucose induced ATP generation in both the wild-type and the mutant cells, whereas glutamine was efficient only in cells expressing hGDH S445L (Fig. 4D) . These results show that glutamine can provide fuel for the mitochondria only in cells carrying the hyperactive hGDH S445L , while the glucose response is not affected.
Cytosolic calcium in INS-1E b-cells expressing hGDH S445L
In the pancreatic b-cells, ATP production is required for closure of the K-ATP channels, depolarization of the cell membrane, and calcium influx necessary for insulin exocytosis. Calcium measurements using Fura-2 fluorescence showed that cell membrane depolarization induced by 30 mM KCl induced similar elevations of cytosolic calcium in INS-1E cells expressing the hGDHwt and the hGDH S445L (Fig. 5A) . Glucose stimulation resulted in robust calcium rises in both wild-type and mutant cells (Fig. 5B) . In contrast, glutamine stimulation was most effective in raising cytosolic calcium in INS-1E cells expressing the hGDHS445L mutant (Fig. 5C ). These data show that hGDH S445L confers to the cell glutamine responsiveness without affecting the operation of the K-ATP pathway per se (Fig. 5D ).
Insulin secretion in cells expressing hGDH S445L
At this point, data show that INS-1E b-cells expressing hGDH S445L exhibit glutamine-stimulated mitochondrial metabolism, ATP production and increase in cytosolic calcium. This suggests that the mutation hGDHS445L may confer to b-cells glutamine responsiveness regarding insulin secretion, which was next tested in INS-1E cells, mouse islets lacking endogenous GDH (isolated from b-Glud1 À/À mice), and human islets. Figure 6A shows the efficiency of adenoviral transduction of hGDHwt and hGDH S445L by immunoblotting performed on the different cell preparations, showing similar levels of GDH in the transduced wild-type and mutant cells. Of note, some background expression of GDH was noticed in non-transduced islets of b-Glud1 À/À mice, accounting for 8-15% of ectopic expression in hGDHwt and hGDH S445L transduced islets (GDH/actin signal density: 0.04 6 0.02, 0.28 6 0.01, 0.51 6 0.08; respectively). We first measured insulin release from INS-1E cells during the culture, i.e. when exposed to regular complete culture medium (RPMI-1640) containing both glucose (11.1 mM) and the regular mix of amino acids including 2 mM glutamine. This showed that the mutant cells secreted more insulin compared to the wild-type cells (Fig. 6B) . Next, in order to discriminate between potential secretagogues, INS-1E cells were tested for their secretory responses upon acute stimulation with 15 mM glucose, 5 mM glutamine, and 30 mM KCl; the latter being used to increase cytosolic calcium independently of mitochondrial activation. Compared to cells expressing the hGDHwt, those expressing hGDH S445L exhibited similar insulin secretion rate in response to glucose and KCl (Fig. 6C) . In contrast, glutamine was a secretagogue only in the mutant INS-1E cells, being as efficient as high glucose. In order to test the effects of hGDH S445L without the potential contribution of endogenous GDH, we also introduced the mutant and wild-type forms of human GDH in mouse islets knocked out for the Glud1 gene specifically in their b-cells (b-Glud1 À/À mouse islets). These "humanized"
islets responded normally to intermediate and high glucose as well as to KCl stimulations, without significant differences between wild-type and mutant islets (Fig. 6D) . Islets expressing the human wild-type GDH did not respond to glutamine stimulation, while those carrying the hyperactive form exhibited robust insulin secretion. Finally, human islets were transduced with hGDHwt and hGDH S445L adenoviruses resulting in similar expression levels of wild-type and mutant GDH, respectively (Fig. 7A) ; and were then assayed for their secretory responses (Fig. 7B) . Basal insulin release at 2.8 mM glucose was higher in human islets expressing hGDH S445L , although insulin secretion stimulated with 16.7 mM glucose reached similar levels when compared to hGDHwt islets. This pattern, similarly observed as a trend in INS-1E cells (Fig. 6C) , might be contributed by active metabolism of the remaining intracellular stores of glutamine (25) , favored by the mutation. Glutamine was not a secretagogue in the wildtype islets, while we observed a secretory response to the amino acid in mutant islets. Overall, secretion data show that the hGDH S445L mutation converts b-cells from non-responsive to glutamine stimulation into responsive to this amino acid through induction of its mitochondrial metabolism (Fig. 7C ).
Ammonia production in hepatocytes expressing hGDH S445L
Besides the hyperinsulinism and the accompanying hypoglycemia, HI/HA patients carrying the mutant form of GDH also have increased circulating ammonia levels contributed by the liver (26) . In this context, we investigated the effects of adenovirusmediated expression of hGDHwt and hGDH S445L in isolated mouse hepatocytes. Immunoblotting analysis shows the expression of GDH in cultured hepatocytes transduced with hGDHwt and hGDH S445L (Fig. 8A) . After starvation, the cells were stimulated with 10 mM glutamine or 20 mM alanine and then the ammonia levels were measured in the medium (Fig. 8B) . Although both amino acids are important substrates for gluconeogenesis, the ammonia production from glutamine is contributed by both deamidation by glutaminase producing glutamate and further deamination by GDH generating aKG; while alanine solely relies on GDH for ammonia production. Upon glutamine exposure, both wild-type and mutant hepatocytes increased ammonia production to similar levels compared to nonstimulated basal conditions. However, when stimulated with alanine, ammonia generation was higher in the hepatocytes expressing hGDH S445L versus hGDHwt (Fig. 8B ). These results demonstrate that the hGDH S445L mutant form causes elevated production of ammonia from hepatocytes (Fig. 8C ).
Discussion
The GDH S445L point mutation is the result of a transition from Serine TCG to Leucine TTG codon. This mutation is frequent among HI/HA patients and is mostly sporadic, inherited in a few cases (8) . Our study characterized the molecular and enzymatic properties of the S445L GDH mutation and uncovered its effects in b-cells and hepatocytes. In the absence of allosteric modulators, the enzymatic activity of hGDH S445L was slightly higher compared with hGDHwt when stimulated with glutamate in the anaplerotic oxidative direction. However, the cataplerotic reductive activity upon aKG stimulation was much stronger with the mutant than with the wild type GDH. Addition of one or the other allosteric modulator changed the anaplerotic activity in a similar way for both hGDHwt and hGDH S445L , i.e. increased activity by ADP and decreased activity by GTP. As opposed to the wild type GDH, when ADP and GTP were combined the mutant GDH remained responsive to ADP allosteric activation, at least at the lower GTP concentrations. GDH activity measured in the cataplerotic reductive direction revealed that hGDH S445L was much more sensitive to ADP-mediated activation compared to hGDHwt, although both enzymes could be inhibited by GTP with a right-shifted dose response for the mutant. At higher ADP concentrations, the hypersensitivity of hGDH S445L to ADP could not be counteracted by GTP at any of the aKG concentrations tested. This mechanism explains the weaker GTP response of the hGDH S445L versus the hGDHwt, primarily driven by much higher sensitivity of the mutant to the ADP activator. Previously, only one activating mutation (D123A) was reported to accentuate ADP activation with no effect on GTP inhibition (27) . Although distant from the ADP-binding site, it was suggested that this GDH Asp123Ala mutation might impair interactions normally forming between Asp-123 and Arg-463, thereby improving the ability of ADP to open the catalytic cleft. Nevertheless, the S445L mutation characterized in this study confers to GDH an atypical dysregulation among hyperactive GDH mutants associated with HI/HA (28) . At the cellular level, INS-1E b-cells expressing the mutant hGDH S445L enzyme responded similarly to hGDHwt in terms of glucose-induced mitochondrial activation and ATP generation. In contrast, upon glutamine exposure only the cells expressing the hyperactive mutant GDH increased respiration and ATP production, as opposed to the control cells. Interestingly, drug-induced uncoupled respiration revealed that hyperactive GDH can compete with dehydrogenase activity of respiratory chain complex I, at least in the NADH-consuming cataplerotic direction.
The glutamine-stimulated mitochondrial activation and ATP rise observed in the mutant INS-1E b-cells were associated with the downstream signalling cascade, i.e. an increase in cytosolic calcium. As expected, this was not the case in the wild-type cells since normal b-cells require elevated glucose concentrations to enhance the mitochondrial respiration and ATP production, followed by the calcium rise. In the mutant cells, glutamine that is deamidated to glutamate is further processed to a-KG by hGDH S445L mutant, thereby enhancing TCA cycle activity, mitochondrial respiration and ATP production (Fig. 7C) . In normal b-cells, this anaplerotic pathway is not efficient, as wild type GDH prevents the conversion of glutamine-derived glutamate to TCA cycle intermediates and subsequent CO 2 production (24) . Of note, overexpression of wild type GDH is not sufficient as such to induce the anaplerotic route that is required in the b-cell for the conversion of glutamine into a secretagogue (14) . Such a tissue-specific forbidden pathway avoids an undesired amino acid-stimulation of insulin secretion, in particular during fasting state when gluconeogenic amino acids are recruited from the skeletal muscles for hepatic glucose production. Consistent with observations on mitochondrial activation, our study demonstrates that amino acid stimulation triggers insulin secretion in b-cells expressing the hyperactive hGDH S445L enzyme, which is not the case in normal b-cells. In response to glucose stimulation, the main physiological insulin secretagogue, similar rates of insulin release were observed in the wild type and the mutant cells. Both hGDHwt and hGDH S445L expressing cells also properly responded to KCl stimulation that was used to induce membrane depolarization and a calcium rise, thereby triggering insulin secretion in a metabolismindependent way. Thus, at basal glucose concentration glutamine is a secretagogue only in cells expressing the hGDH S445L mutation. This phenotype was observed similarly in cells expressing both the endogenous wild type and the mutant GDH (in INS-1E b-cells and human islets) as well as in cells This indicates that the mutation exerts a dominant dysfunction within the GDH heterohexamer, consistent with the phenotype of HI/HA patients being in majority heterozygous according to major proportion of sporadic cases. Our data suggest that in HI/ HA patients the mutant GDH S445L enzyme would be constitutively hyperactive because of the high sensitivity to the allosteric activator ADP. More specifically, the normally forbidden anaplerotic GDH direction in b-cells would be activated, allowing glutamine-induced TCA cycle activation and subsequent ATP production, calcium rise, and ultimately hyper insulin secretion (Fig. 7C) . HI/HA patients carrying the S445L GDH mutation are also characterized by hyperammonemia (HA). In this context, we measured ammonia production in mouse hepatocytes expressing the mutant GDH under basal condition or stimulated with the predominant circulating amino acids, i.e. alanine and glutamine. Both amino acids increased ammonia production in the wild-type and mutant hepatocytes compared to basal condition. However, alanine stimulation led to higher ammonia release from the hepatocytes expressing the hGDH S445L versus hGDHwt. These GDH-dependent differences are in agreement with a role for alanine as a gluconeogenic amino acid generating pyruvate and glutamate through alanine aminotransferase. The thus formed glutamate is a substrate for the GDH oxidative activity generating ammonia, which was produced at a higher rate in hepatocytes carrying the hyperactive mutant GDH. These data provide an explanation for the HA observed in patients carrying the S445L GDH mutation. Regarding glutamine, hepatocytes convert this amino acid into glutamate by deamidation, a reaction catalysed by glutaminase, followed by deamination through GDH (Fig. 8C) . Overall, glutamine-mediated ammonia production is contributed by both glutaminase and GDH, the former eventually masking potential differences in the activity of the latter. Indeed, as opposed to alanine stimulation, when incubated with glutamine the mutant hepatocytes released similar levels of ammonia compared to the wild type cells. In the liver, the conversion of glutamate into N-acetylglutamate, an allosteric activator of carbamoyl phosphate synthetase, enhances the urea cycle and promotes ammonia detoxification. Our results indicate that in hepatocytes expressing the mutant hGDH S445L the alanine-derived glutamate was converted to a-KG and ammonia at a higher rate than in control cells (Fig. 8C) . This may lead to the depletion of the glutamate pool necessary for the synthesis of N-acetylglutamate, thereby reducing the efficiency of ammonia detoxification.
The characterization of the hGDH S445L mutant demonstrates its hypersensitivity to the allosteric activator ADP, an effect poorly counterbalanced by the inhibitory action of GTP. This molecular defect differs from other HI/HA-associated GDH mutations also located in the protrusion antenna region. In particular, the well characterized GDH S448P and GDH H454Y mutations exhibit loss of GTP response since these mutant residues impede the interaction of GTP with its binding domain (28, 29) . In contrast, the partial loss of GTP-mediated inhibition of the GDH S445L enzyme appears to be primarily mediated by the hypersensitivity to ADP, a mechanism specific for this mutation. Interestingly, substitution of Serine for Arginine at the very close position 443 markedly reduces the sensitivity to ADP (30) , pointing again to this region as a key regulator for the ADP response.
In conclusion, the present study shows that the GDH S445L enzyme is highly sensitive to the allosteric activator ADP, explaining the hyperactivity of this mutant. INS-1E b-cells expressing GDH S445L responded to glutamine stimulation by increasing the mitochondrial respiration and ATP production, as well as by a rise in cytosolic calcium. This was associated with the elevation of insulin secretion, which was similarly observed in mouse and human pancreatic islets expressing the mutant GDH S445L , thereby recapitulating the hyperinsulinemia and subsequent hypoglycemia observed in affected children following a protein meal. Furthermore, hepatocytes expressing the GDH S445L enzyme produced more ammonia than control cells, consistent with the hyperammonemia characterizing HI/HA patients. At the present time, treatment strategy regarding HI/HA patients is based on a controlled protein-poor carbohydrate-rich diet and with diazoxide to inhibit b-cell function by activation of the K-ATP channel. Future therapies should benefit from molecular characterization of GDH mutants for the design of new drugs matching the specificities of such mutations.
Experimental Procedures
Cell culture gen plates in culture medium (Williams E-medium, 5% FCS, 1 nM insulin, 1 mM Dexamethasone, 100 U/ml penicillin, 100 lg/ ml streptomycin, 1% Glutamax) at 37 C. The day after the hepatocytes were transduced with $10 ifu/cell of adenoviruses for 3 h and then the cells were washed with new medium and kept in culture at 37 C and 5% CO 2 for 48 h.
Animals
For b-cell-specific GDH knockout islets, Glud1 fl/fl floxed animals (Glud1
, MGI:3835667) were crossed with Rip-Cre mice expressing the Cre recombinase under the rat insulin promoter in order to obtain homozygous bGlud1 À/À mice (11). Mice were maintained on a mixed (C57BL/6J Â 129/Sv) genetic background. Mouse breeding and handling was carried out in our local certified animal facility according to procedures that were approved (authorization #1034/3615/1-R) by the animal care and experimentation authorities of the Canton of Geneva.
Adenovirus construction
Recombinant adenoviruses encoding for the human GLUD1 wild-type and the S445L mutant under the cytomegalovirus (CMV) promoter were generated using the Adeno-X Expression system as described previously (33) . The full-length human GLUD1 cDNA was obtained from the plasmid hGLUD1-pcDNA3, which was kindly provided by Dr C.A. Stanley and Dr B. Y. Hsu (The Children's Hospital of Philadelphia, Philadelphia, Pa., USA). The human GLUD1 gene was amplified from the pcDNA3 plasmid by PCR using the forward primer containing the PmeI restriction site upstream of the GLUD1 start codon (5'-ATAAGTTTAAACTATGTACCGCTACCTGGGCGAAG-3') and the reverse primer containing the NotI and SpeI site downstream the stop codon (5'-TACTAGTGCGGCCGCCTATGTGAAGGTCACACC AGCTTCATTGTAC-3'). This PCR fragment was digested with PmeI and NotI restriction enzymes and sub-cloned in the multiple cloning site of the pTRE-Shuttle2 plasmid, previously opened with the same enzymes. The original pTRE-Shuttle2 plasmid contained the TetON inducible mCMV (murine cytomegalovirus) promoter described previously (34) . A non-inducible CMV promoter was cut off from the hGLUD1-pcDNA3 plasmid by MluI and NheI digestion and sub-cloned in the pTRE-Shuttle2 plasmid, previously opened with the same enzymes. The final hGLUD1-pTRE-Shuttle2 plasmid was used as a PCR template to realize the point mutation at nucleotide position 1743 of GLUD1 gene. The GLUD1 gene sequence was amplified using a forward primer containing the mutated nucleotide immediately after the ScaI restriction site (5'-AAAAAGTACTGGGTGCATCTGAGAAAGACATCGTG-3') and the reverse primer previously described. The PCR product containing the point mutation was digested by ScaI and NotI restriction enzymes and finally cloned into the hGLUD1-pTREShuttle2 plasmid, previously opened by EcoRV and NotI located in the terminal cloning DNA sequence of GLUD1. Digestion using EcoRV was used to discriminate between the GLUD1 wild type versus S445L mutant, as the latter lost EcoRV digestion site (5'-. . .GAT ATC. . .-3' for 5'-. . .GAT ACT. . .-3', respectively, giving rise to the S445L mutation). After plasmid amplification in E. coli, the GLUD1-specific expression cassette was excised from pShuttle2 by I-CeuI and PI-SceI digestion and ligated to Adeno-X Viral DNA, opened by SwaI. 
Immunoblotting and GDH activity
Protein extraction from INS-1E b-cells and isolated mouse hepatocytes and islets were performed in RIPA buffer by sonication or by freeze/thaw cycles. Protein extracts were separated in bisacrylamide 10% gel and probed with the primary antibodies rabbit anti-GDH (Rockland, Gilbertsville, PA, USA), mouse anti-actin (Millipore, Billerica MA, USA) and anti-porin (Abcam, Cambridge, MA, USA), as detailed previously (14) . Bands were revealed by horseradish peroxidase detection system. GDH enzymatic activity was measured as described before (14) . For GDH enzymatic activity, cells were extracted and lysed in 20 mM Tris-HCl pH 8.0, 2 mM CDTA and 0.2% Tween-20. GDH activity was measured in both cataplerotic and anaplerotic directions in 1.5 ml buffer (50 mM Tris-HCl pH 9.5, 2.6 mM EDTA, plus NADH or NAD as indicated) using a Fluostar Optima (BMG Labtech) and monitored as NADH auto-fluorescence excited at 340 nm and recorded at 470 nm. After equilibration, the addition of the indicated concentrations of substrates a-ketoglutarate (cataplerosis) or L-glutamate (anaplerosis) initiated the reaction. The GDH enzymatic activity was calculated as initial velocity from standard curve and normalized to actual GDH concentration determined by immunoblotting (mU/ng of GDH enzyme per min). The standard curve was obtained from the enzymatic activity of purified GDH from bovine liver (G-2626, Sigma) at different concentrations (0, 2.625, 5.25, 10.5, 21, and 42mg/ml). ] i was measured at 2.5 mM glucose for 8 min and then the cells were stimulated with 15 mM glucose or 5 mM glutamine before addition of 30 mM KCl. The [Ca 2þ ] i was measured by Fura-2 fluorescence in a Fluostar Optima using alternating excitation wavelengths of 340 and 380 nm and recording emission at 510 nm.
Mitochondrial respiration and calcium assay

ATP quantification assay
INS-1E cells (5 Â 10 5 ) were plated in polyornithine-treated 6-well plates and cultured in complete RPMI-1640 medium with 5% FCS for 4 days before transduction as described above. One day after transduction, cells were washed and starved for 2h with glucose-and glutamine-free RPMI-1640 medium at 37 C followed by pre-incubation with glucose-free KRBH for 30 min and then incubated for 10 min with 2.5 mM and 15 mM glucose, 2.5 mM glucose plus 5 mM glutamine. At the end of the incubation period, reaction was stopped by putting cell plates on ice, supernatants were removed and cells were extracted with 1 ml of lysis buffer (20 mM Tris-HCl pH 8.0, 2 mM CDTA and 0.2% Tween-20). Extracts were centrifuged and the supernatant was collected and kept at -20 C before the protein and ATP quantification assay. The protein quantification was done by the Bradford colorimetric assay (Sigma) and the ATP concentrations measured luciferase Bioluminescence assay kit CLS II (Roche).
Islet isolation and adenoviral transduction
Pancreatic islets were isolated from male Glud1 À/À mice by collagenase digestion and cultured as described before (14) . Human islets were isolated from pancreases of deceased multiorgan donors who had provided written informed consent (ECIT consortium) and maintained for a standard recovery period of
